Clinical Trials Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Nov 14, 2022; 28(42): 6068-6077
Published online Nov 14, 2022. doi: 10.3748/wjg.v28.i42.6068
Table 1 Characteristics of the patients
Characteristic
Value
Sex as female/male, n4/24
Age, yr, mean ± SD53.7 ± 10.4
Height, cm, mean ± SD169.4 ± 5.8
Weight, kg, mean ± SD62.9 ± 11.6
Previous episodes of variceal bleeding, mean ± SD3 ± 2
Treatment history, n (%)
β blockade only3 (10.7)
Sclera therapy only4 (14.3)
β blockade and sclerotherapy21 (75.0)
Child-Pugh stage, n (%)
A11 (39.3)
B16 (57.1)
C1 (3.6)
Ascites, n (%)
None17 (60.7)
Mild2 (7.1)
Severe9 (32.1)
HVPG, mmHg, n (%)
< 1210 (35.7)
≥ 1218 (64.3)
Table 2 Comparison of the moderate and severe portal hypertension groups
Index
Moderate PH
Severe PH
P value
Sex as female/male2/82/160.520
Age, yr54.2 ± 10.953.4 ± 10.50.848
Height, cm168.0 ± 6.0170.1 ± 5.60.362
Weight, kg64.8 ± 12.361.8 ± 11.40.528
Child-Pugh score7.1 ± 1.97.8 ± 1.80.023
HVPG9.6 ± 1.318.9 ± 4.40.000
Perfusion CT
LBF114.6 ± 36.087.9 ± 24.80.029
LBV19.7 ± 3.015.5 ± 2.20.000
HAF as × 10-28.2 ± 2.38.7 ± 4.70.731
SBF96.0 ± 30.0108.7 ± 31.40.308
SBV13.9 ± 2.911.9 ± 2.50.084